- $567.39m
- $619.65m
- $216.39m
- 58
- 34
- 31
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.89 | ||
| Price to Tang. Book | 4.05 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.11 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -17.28% | ||
| Return on Equity | -29.23% | ||
| Operating Margin | -21.2% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 106.28 | 110.98 | 147.46 | 181.38 | 216.39 | 255.73 | 301.96 | 19.45% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | -14.84 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Paragon 28, Inc. is a medical device company focused on the foot and ankle orthopedic market. The Company provides orthopedic solutions, procedural approaches and instrumentation that cover a range of foot and ankle ailments, including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot and orthobiologics. To treat these painful, debilitating or even life-threatening conditions, it provides a portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. Its broad suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. It has developed a comprehensive portfolio of foot and ankle surgical systems. Each system typically includes plates, screws, staples, nails, advanced joint and bone replacements, orthobiologics, and other implantation instruments and disposables specifically designed for the particular surgical system.
Directors
- Albert DaCosta PRE
- Jim Riegler CFD
- Francis Bono CFD
- Lee Rosenthal CFD
- Brendan Shook EVP
- Matt Jarboe OTH
- B. Kristine Johnson DRC (69)
- Kristina Wright DRC
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- October 8th, 2021
- Public Since
- October 21st, 2021
- No. of Shareholders
- 86
- No. of Employees
- 430
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 82,951,360
- Address
- 14445 Grasslands Drive, ENGLEWOOD, 80112
- Web
- https://paragon28.com/
- Phone
- +1 7209121332
- Auditors
- Deloitte & Touche LLP
Upcoming Events for FNA
Q3 2024 Paragon 28 Inc Earnings Release
Similar to FNA
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
Avanos Medical
New York Stock Exchange
FAQ
What is the Paragon 28 share price?
As of Today at 22:35 UTC, shares in Paragon 28 are trading at $5.74. This share price information is delayed by 15 minutes.
How has the Paragon 28 share price performed this year?
Shares in Paragon 28 last closed at $5.74 and the price had moved by -68.06% over the past 365 days. In terms of relative price strength the Paragon 28 share price has underperformed the S&P500 Index by -74.58% over the past year.
What are the analyst and broker recommendations for Paragon 28?
The overall consensus recommendation for Paragon 28 is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Paragon 28 dividend yield?
Paragon 28 does not currently pay a dividend.
Does Paragon 28 pay a dividend?
Paragon 28 does not currently pay a dividend.
When does Paragon 28 next pay dividends?
Paragon 28 does not currently pay a dividend.
How do I buy Paragon 28 shares?
To buy shares in Paragon 28 you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Paragon 28?
As of the previous close price of $5.74, shares in Paragon 28 had a market capitalisation of $476.14m.
Where are Paragon 28 shares listed?
Here are the trading details for Paragon 28:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: FNA
What kind of share is Paragon 28?
Based on an overall assessment of its quality, value and momentum Paragon 28 is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Paragon 28 share price forecast for 2024?
The analyst consensus target price for shares in Paragon 28 is $16.00. That is 178.75% above the last closing price of $5.74.
Analysts covering Paragon 28 currently have a consensus Earnings Per Share (EPS) forecast of -$0.58 for the next financial year.
What is the trend in the Paragon 28 share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Paragon 28. Over the past six months, its share price has underperformed the S&P500 Index by -59.75%.
As of the last closing price of $5.74, shares in Paragon 28 were trading -46.15% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Paragon 28 PE Ratio?
The Paragon 28 PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.74.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Paragon 28?
Paragon 28's management team is headed by:
- Albert DaCosta - PRE
- Jim Riegler - CFD
- Francis Bono - CFD
- Lee Rosenthal - CFD
- Brendan Shook - EVP
- Matt Jarboe - OTH
- B. Kristine Johnson - DRC
- Kristina Wright - DRC